Biotech Takeover Targets Wall Street Eyes After Apogee Deal
AbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
Deciding whether zero based or traditional budgeting is better depends on your financial goals. Explore both to find the right fit for you.
25,778 articlesAbbVie’s Apogee deal has revived takeover chatter. Three Nasdaq-listed biotech players are emerging as plausible biot...
A late-stage setback for Jazz Pharmaceuticals' lung cancer drug Zepzelca rattled investors, but the larger story may ...
A growing wave of retirees is carving out a separate income sleeve in their retirement portfolios to fund gifts and e...
A common Medicare timing error can leave retirees exposed to coverage gaps. The 8-month Special Enrollment Period sta...
In a choppy market, one defense contractor shines as a rare dividend stock built for downturns. Its government-backed...
Schwab U.S. Dividend Equity ETF SCHD remains a cornerstone for income investors as of mid-2026, combining a low fee w...
Dormant Ethereum addresses moved more than 33,600 ETH, revealing a test of demand around the $1,500 level as ethereum...
In a volatile market, CVS Health leads a retirement-focused view of the magic formula, topping Qualcomm and Valero as...
Marvell Technology is drawing fresh investor attention as analysts map a path to a $1 trillion market cap by 2032, po...
Ethereum hovers around $1,585 after a sharp weekly slide, with analyst Tom Lee arguing that quarter-end window dressi...
Bitcoin faces renewed selling from large holders while smaller investors buy the dip. On-chain data reveals a widenin...
Two Nasdaq-100 trackers offer the same index path, but a small fee delta has produced a 6.86% trailing return gap ove...